睿知中国医院研究地图
候选清单

正在招募淋巴瘤早期I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由上海市第一人民医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方上海市第一人民医院Shanghai General Hospital上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07162012,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 70 岁;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed EBV-positive lymphoma (tumor tissue must be EBER-positive as confirmed by in situ hybridization [ISH] or fluorescence in situ hybridization [FISH]), with peripheral blood EBV viral load >10³ copies/mL by quantitative real-time PCR.

    入选标准第 4 条

    Extranodal lesions: longest diameter >10 mm. For patients with bone-marrow-only involvement who have no measurable lesions on imaging, the presence of ≥5% lymphoma cells in bone marrow biopsy or flow cytometry can be considered an evaluable lesion.

    入选标准第 11 条

  3. Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception during the study and for 4 months after the end of treatment.

    入选标准第 22 条

    Recent anti-tumor therapy: less than 4 weeks since last anti-cancer therapy (radiotherapy, chemotherapy, targeted therapy, immunotherapy, or local therapy), or less than 2 weeks since palliative radiotherapy.

    排除标准第 8 条

  4. ECOG performance status <3.

    入选标准第 19 条

  5. Hematologic: absolute neutrophil count ≥1×10⁹/L; hemoglobin ≥70 g/L; platelet count ≥50×10⁹/L;

    入选标准第 13 条

    Hepatic: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × the upper limit of normal (ULN), and total bilirubin (TBIL) ≤ 1.5 × ULN (except when liver function abnormalities are attributable to the underlying disease);

    入选标准第 14 条

    Renal: serum creatinine ≤1.5× ULN;

    入选标准第 15 条

    Coagulation: fibrinogen ≥1.0 g/L; activated partial thromboplastin time (APTT) ≤1.5× ULN; prothrombin time (PT) ≤1.5× ULN.

    入选标准第 17 条

    Hepatitis C virus (HCV): HCV antibody positive and HCV RNA ≥ upper limit of normal (ULN);

    排除标准第 14 条

  6. Measurable disease: At least one measurable lesion according to the 2014 Lymphoma Response Evaluation Criteria:

    入选标准第 9 条

    Nodal lesions: longest diameter >15 mm on contrast-enhanced CT, MRI, or PET-CT;

    入选标准第 10 条

  7. Hepatitis B virus (HBV): HBsAg positive, or HBcAb positive with HBV-DNA above the detection limit of the study center;

    排除标准第 13 条

    Human immunodeficiency virus (HIV) or Treponema pallidum (syphilis) antibody positive;

    排除标准第 15 条

  8. No pregnancy planned during the treatment period;

    入选标准第 21 条

    Pregnant or breastfeeding women.

    排除标准第 9 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07162012,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age 18-70 years, male or female.
  2. HLA genotype at locus A is 11:01.
  3. Disease diagnosis and status:
  4. Histologically or cytologically confirmed EBV-positive lymphoma (tumor tissue must be EBER-positive as confirmed by in situ hybridization [ISH] or fluorescence in situ hybridization [FISH]), with peripheral blood EBV viral load >10³ copies/mL by quantitative real-time PCR.
  5. Disease types include but are not limited to:
  6. Definition of relapse: appearance of new lesions at the primary site or other sites after achieving complete remission (CR).
  7. Definition of refractory disease (meeting any of the following):
  8. Prior treatment requirements:
  9. Measurable disease: At least one measurable lesion according to the 2014 Lymphoma Response Evaluation Criteria:
  10. Nodal lesions: longest diameter >15 mm on contrast-enhanced CT, MRI, or PET-CT;
  11. Extranodal lesions: longest diameter >10 mm. For patients with bone-marrow-only involvement who have no measurable lesions on imaging, the presence of ≥5% lymphoma cells in bone marrow biopsy or flow cytometry can be considered an evaluable lesion.
  12. Adequate organ function, defined as:
  13. Hematologic: absolute neutrophil count ≥1×10⁹/L; hemoglobin ≥70 g/L; platelet count ≥50×10⁹/L;
  14. Hepatic: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × the upper limit of normal (ULN), and total bilirubin (TBIL) ≤ 1.5 × ULN (except when liver function abnormalities are attributable to the underlying disease);
  15. Renal: serum creatinine ≤1.5× ULN;
  16. Cardiac: left ventricular ejection fraction (LVEF) ≥50%;
  17. Coagulation: fibrinogen ≥1.0 g/L; activated partial thromboplastin time (APTT) ≤1.5× ULN; prothrombin time (PT) ≤1.5× ULN.
  18. Expected survival >3 months.
  19. ECOG performance status <3.
  20. Contraception requirements:
  21. No pregnancy planned during the treatment period;
  22. Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception during the study and for 4 months after the end of treatment.
  23. Willingness to participate in the study, ability to sign informed consent, comply with the study protocol, and availability of peripheral venous access for lymphocyte collection.

排除标准:Exclusion Criteria:

  1. History of other malignancies, except for:
  2. Basal cell carcinoma of the skin;
  3. Squamous cell carcinoma of the skin;
  4. Superficial bladder cancer;
  5. Carcinoma in situ of the cervix;
  6. Gastrointestinal mucosal carcinoma in situ;
  7. Other malignancies considered acceptable by the investigator (must have received curative treatment with no recurrence within the past 5 years).
  8. Recent anti-tumor therapy: less than 4 weeks since last anti-cancer therapy (radiotherapy, chemotherapy, targeted therapy, immunotherapy, or local therapy), or less than 2 weeks since palliative radiotherapy.
  9. Pregnant or breastfeeding women.
  10. Presence of severe medical conditions such as intracranial hypertension, impaired consciousness, respiratory failure, or disseminated intravascular coagulation (DIC).
  11. Severe organ dysfunction, including:
  12. Known active infections or positive screening results for:
  13. Hepatitis B virus (HBV): HBsAg positive, or HBcAb positive with HBV-DNA above the detection limit of the study center;
  14. Hepatitis C virus (HCV): HCV antibody positive and HCV RNA ≥ upper limit of normal (ULN);
  15. Human immunodeficiency virus (HIV) or Treponema pallidum (syphilis) antibody positive;
  16. Active tuberculosis (TB) (must be excluded by chest X-ray, sputum test, and clinical symptoms) or history of active TB;
  17. Severe acute or chronic infections requiring systemic treatment.
  18. Active central nervous system (CNS) disease (e.g., tumor metastasis, infection, demyelinating disease), including untreated lesions, progressive disease on imaging or symptoms requiring urgent intervention, or requiring high-dose immunosuppressive therapy for control.
  19. Receiving systemic corticosteroid therapy prior to screening and judged by the investigator to require long-term systemic corticosteroid treatment during the study (excluding inhaled or topical use); or receiving systemic corticosteroid treatment within 72 hours before cell infusion (excluding inhaled or topical use).
  20. Presence of graft-versus-host disease (GVHD), defined as grade ≥2 acute GVHD or moderate/severe chronic GVHD, or current use of immunosuppressive therapy.
  21. History of severe allergic reactions to drugs or excipients required in this study, or history of allergy to tocilizumab.
  22. Any condition that, in the opinion of the investigator, makes the subject unsuitable for study participation.

引自 ClinicalTrials.gov, NCT07162012, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07162012,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07162012